1. Introduction
===============

Semaphorins are a large family of transmembrane or glycosylphosphatidylinositol-linked proteins, which are grouped into eight classes \[[@b1-ijms-13-13264]\]. Initially, the function of semaphorins has been best described in the nervous system. Recently, studies proved semaphorins are important players during angiogenesis, as they regulate blood vessel growth and endothelial cell homing during vessel development \[[@b2-ijms-13-13264]\]. Semaphorin4D (SEMA4D, also known as CD100), a member of the semaphorin IV subfamily, has been found to promote angiogenesis upon binding its receptor Plexin-B1 both *in vitro* and *in vivo* \[[@b3-ijms-13-13264],[@b4-ijms-13-13264]\].

Angiogenesis is essential for the growth, invasion, and metastasis of tumors \[[@b5-ijms-13-13264]\]. Hypoxia-inducible factor-1 (HIF-1) is a major regulator of cell adaptation to hypoxic stress and plays a critical role in tumorigenesis and angiogenesis \[[@b6-ijms-13-13264]\]. HIF-1 is a heterodimer composed of two subunits: HIF-1α and HIF-1β. HIF-1α is the oxygen-regulated subunit that determines HIF-1 activity. Under hypoxic conditions, HIF-1 transcriptional activity increases rapidly due to HIF-1α protein over-expression \[[@b7-ijms-13-13264]\]. HIF-1 binds to hypoxia response elements (HRE) in the promoter of target genes and activates their expression to mediate adaptive responses to decreased oxygen concentration, such as the formation of new blood vessels via proliferation and migration of endothelial cells toward the developing tumor \[[@b8-ijms-13-13264]\]. This response is influenced by increased production of pro-angiogenic proteins such as vascular endothelial growth factor (VEGF). Moreover, like other pro-angiogenic factors, semaphorins may be regulated by changes in oxygen tension \[[@b9-ijms-13-13264]\].

A recent study indicated that SEMA4D is induced by hypoxia in a HIF-1 dependent manner and influences tumor vascularity in head and neck squamous cell carcinoma (HNSCC) \[[@b10-ijms-13-13264]\] in a manner analogous to VEGF in order to attract Plexin-B1-expressing endothelial cells into the tumor for the purpose of promoting growth and vascularity. It also demonstrated that SEMA4D cooperated with VEGF to promote angiogenesis \[[@b11-ijms-13-13264]\]. Complementally, SEMA4D, which is under the control of the HIF-family of transcription factors, cooperates with VEGF to promote tumor growth and vascularity in oral squamous cell carcinoma \[[@b12-ijms-13-13264]\].

Epithelial ovarian cancer (EOC) is the leading killer among all gynecological malignancies \[[@b13-ijms-13-13264]\]. Tumor angiogenesis had been found to have important prognostic significance in advanced ovarian cancer \[[@b14-ijms-13-13264]\]. However, the function and expression of SEMA4D in EOC is not very well understood. Here, we examine the expression of SEMA4D, HIF-1α and VEGF in normal and cancerous ovarian tissues and assess their association with the established clinicopathologic factors of the disease as well as patient prognosis.

2. Results
==========

2.1. Higher Expression of SEMA4D, HIF-1α and VEGF in Ovarian Cancer than in Normal Ovarian Tissues
--------------------------------------------------------------------------------------------------

Immunohistochemistry revealed that 61.3% (76/124), 41.9% (52/124) and 48.4% (60/124) of ovarian cancer tissues stained positively for SEMA4D, VEGF and HIF-1α, which were significantly higher than the positive staining in normal ovarian epithelial tissues (61.3% *vs.* 10%, 41.9% *vs.* 10%, and 48.4% *vs.* 5%, *p* \< 0.001, respectively; [Table 1](#t1-ijms-13-13264){ref-type="table"}). [Figure 1](#f1-ijms-13-13264){ref-type="fig"} shows the representative immunohistochemistry results.

2.2. Positive Correlation between the Expression of SEMA4D and HIF-1α or VEGF in Ovarian Cancer
-----------------------------------------------------------------------------------------------

Among 76 EOC tissues stained positively for SEMA4D, 52.6% (40/76) stained positively for VEGF and 63.2% (48/76) stained positively for HIF-1*α*. Likewise, among 60 EOC tissues stained positively for HIF-1α, 65.0% (39/60) stained positively for VEGF. The correlation of SEMA4D, VEGF and HIF-1α expression were closely (*ρ* = 0.263, 0.349 and 0.412, *p* \< 0.05, respectively, see [Table 2](#t2-ijms-13-13264){ref-type="table"}).

2.3. Expression of HIF-1α, VEGF and SEMA4D and Clinicopathologic Characteristics of EOC Patients
------------------------------------------------------------------------------------------------

As shown in [Table 3](#t3-ijms-13-13264){ref-type="table"}, over-expressions of SEMA4D and HIF-1α were closely related to EOC tissues with low histologic grade, advanced FIGO stage and lymph node (LN) metastasis (*p* \< 0.05). Furthermore, over-expression of SEMA4D was also related to residual disease ≥1 cm. Over-expression of VEGF was closely related to EOC tissues with low histologic grade, advanced FIGO stage, chemotherapy resistance, and platinum resistant and refractory (*p* \< 0.05). These results suggest that over-expression of HIF-1, VEGF and SEMA4D are associated with a more malignant ovarian cancer phenotype.

2.4. Survival Analysis of Prognosis Factors in EOC
--------------------------------------------------

In univariate analysis, the media of OS and PFS were associated with the histologic grade, FIGO stage, LN metastasis, residual disease, tumors' sensitivity to chemotherapy, response to chemotherapy, and expressions of HIF-1α and SEMA4D (*p* \< 0.05, [Table 4](#t4-ijms-13-13264){ref-type="table"}). Furthermore, as seen in [Table 5](#t5-ijms-13-13264){ref-type="table"}, multivariate Cox analysis showed that advanced stage, low histologic grade and positive SEMA4D expression were the independent factors for evaluation of OS (*p* \< 0.05). Additionally, low histologic grade and positive SEMA4D expression were the independent factors for evaluation of PFS (*p* \< 0.05). Thus, patients with positive SEMA4D expression showed shorter OS and PFS than those with negative expression ([Figure 2](#f2-ijms-13-13264){ref-type="fig"}).

3. Discussion
=============

There are striking similarities between the process of nerve growth and blood vessel branching \[[@b2-ijms-13-13264]\]. SEMA4D, a protein originally shown to regulate axonal growth in the developing nervous system, has been identified as promoting angiogenesis in tumor progression.

Although SEMA4D has been previously explored in many types of cancer, including HNSCC, prostate cancer, colon cancer, breast cancer and lung cancer, its function remains unknown in ovarian cancer. In this study, data revealed SEMA4D positive expression in EOC tissues was obviously higher than in normal ovarian epithelial tissues.

The dimeric transcription factor HIF-1 is the key regulator of cellular response to hypoxia. HIF-1α is the regulatory subunit of HIF-1 and determines its activity. The HIF-1 heterodimer binds to HREs in the cis-acting sequences of target genes including VEGF, which is involved in adaptive pathways like angiogenesis \[[@b15-ijms-13-13264]\]. VEGF, a pro-angiogenic factor whose expression increases upon cellular exposure to low oxygen tension, plays a crucial role in stimulating the switch from a hypoxic, avascular phenotype to a pro-angiogenic phenotype in growing tumors \[[@b16-ijms-13-13264]\]. In the present study, we also found the positive expressions of VEGF and HIF-1α in EOC were significantly higher than in normal ovarian epithelial tissues.

Notably, previous studies had proved this angiogenic response elicited by SEMA4D was comparable to that by other well-known agiogenic molecules such as VEGF, HGF and bFGF and was dependent of up-regulation of these molecules \[[@b4-ijms-13-13264],[@b17-ijms-13-13264]\]. HIF-1α accumulates in the cytoplasm and is translocated to the nucleus to perform transcriptional activity, which includes inducing expression of its downstream signaling molecule VEGF \[[@b18-ijms-13-13264]\]. In addition, Zhou *et al*. \[[@b11-ijms-13-13264]\] examined the contribution of SEMA4D to tumor-induced angiogenesis when compared to VEGF and suggested that targeting these proteins might represent a complementary or parallel mode of treatment for anti-angiogenic therapy of HNSCC and other solid tumors exhibiting insensitivity of anti-VEGF therapy. Moreover, our results showed that SEMA4D expression was positively correlated with HIF-1α and VEGF expression.

Furthermore, we found that over-expression of SEMA4D, VEGF and HIF-1α were all closely related to low histologic grade and advanced stage, while indicating a shorter OS, which was partially consistent with a previous study that reported HIF-1 and VEGF were associated with poor prognosis of ovarian cancer patients \[[@b19-ijms-13-13264]\]. We therefore hypothesize that SEMA4D may be another pro-angiogenic factor in the downstream signaling pathway of HIF-1α, though further studies are needed to test this hypothesis.

The next univariated and multivariate survival analysis showed that low histologic grade and SEMA4D over-expression were the independent factors for predicting OS and PFS of EOC patients. Similarly, recent work has revealed a correlation between high levels of SEMA4D expression in some sarcomas and poor overall patient prognosis \[[@b20-ijms-13-13264]\]. Therefore, we speculate that SEMA4D inhibition might offer a promising target for tumor anti-angiogenesis therapy and prevention of metastatic progression and invasion in EOC.

4. Experimental Section
=======================

4.1. Tissue Specimens
---------------------

A total of 40 normal ovarian epithelia and 124 EOC tissues were obtained from patients (median age: 40 years and 50 years, respectively) admitted at the Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital from January 2004 to December 2006. Normal ovarian tissues came from women who underwent surgery for benign or malignant gynecological diseases other than ovarian carcinoma. Tumor specimens were collected from women during primary surgery and prior to the initiation of adjuvant therapy. Approval by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital was obtained in advance, and the informed consent requirement was waived because the current study was performed as a retrospective review. Adjuvant chemotherapy consisted of paclitaxel (175 mg/m^2^) and carboplatin (6 AUC) and no patient was treated with an anti-angiogenic therapy. All patients were followed until death or the end of the follow-up period (March 31, 2012).

4.2. Immunohistochemical Staining
---------------------------------

Sections of 4-mm thick serially cut from formalin-fixed and paraffin-embedded tissue blocks were deparaffinized, rehydrated and autoclave-treated at 121 °C for 10 min in 0.1 M citrate buffer (pH 6.0) to induce antigen retrieval. Endogenous peroxides in the section were blocked by incubation in 3% hydrogen peroxide for 5 min. Then, after being blocked with 0.5% goat serum for 60 min, the sections were incubated at 4 °C overnight with HIF-1α and VEGF primary antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or with SEMA4D (BD Biosciences, San Jose, CA, USA). The DAKO REAL EnVision Detection kit (DAKO) was subsequently applied for 30 min. Finally, sections were incubated in 3,3′-diaminobenzidine for 5 min, followed by Mayer's hematoxylin counterstaining and mounting. Negative controls were obtained by replacing the primary antibody with isotype-matched monoclonal antibody. The percentage of positive cells was rated on the following point scale: no points (negative), ≤10% positive cells, regardless of staining intensity; 2 points, 11%--50% positive cells; 3 points, 51%--80% positive cells; and 4 points, ≥81% positive cells. The staining intensity was rated as follows: 1 point, weak intensity; 2 points, moderate intensity; and 3 points, strong intensity. Points for the percentage of positive cells and staining intensity were added, and specimens were attributed to two groups according to their overall score. Finally, specimens of ≤3 points were rated as negative, or as positive \[[@b21-ijms-13-13264]\]. Two independent investigators blinded to clinical data performed the analysis.

4.3. Statistical Analysis
-------------------------

The spearman rank correlation was used to assess the degree of correlation among variables. The survival rate was determined by the Kaplan-Meier method, and the log rank test was used to determine significance. Factors that were deemed of potential importance by univariate analysis were included in the multivariate analysis. A result was considered significant when the *p* value was \<0.05. All statistical analysis was performed with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

5. Conclusions
==============

In summary, we found SEMA4D expression was positively correlated with VEGF and HIF-1α in EOC and was a novel indicator of poor prognosis for EOC patients. We expect that SEMA4D may serve as a reliable tool for early and accurate prediction of tumor recurrence and may be a potential therapeutic target for EOC patients.

![Representative images showing SEMA4D (**A**--**F**), VEGF (**G**--**I**) and HIF-1α (**J**--**L**) expressions. (**A**) SEMA4D negative expression in normal ovarian epithelia (400×); (**B**) mucinous ovarian adenocarcinoma (G2) with negative immunostaining of SEMA4D (200×); (**C**) serous ovarian adenocarcinoma (G2, FIGO Stage II) with immunostaining of SEMA4D in the membrane of tumor cells (400×; Evaluation: 5 points); (**D**) serous ovarian adenocarcinoma (G3, FIGO Stage I) with immunostaining of SEMA4D (400×; Evaluation: 3 points); (**E**) endometrioid ovarian adenocarcinoma (G2, FIGO Stage III) with immunostaining of SEMA4D (400×; Evaluation: 6 points); (**F**) ovarian adenocarcinoma (G3 to undifferentiated, FIGO Stage III) with immunostaining of SEMA4D (400×; Evaluation: 7 points); (**G**) serous ovarian adenocarcinoma (G2, FIGO Stage I) with immunostaining of VEGF in the cytoplasm of tumor cells (400×; Evaluation: 2 points); (**H**) endometrioid ovarian adenocarcinoma (G2, FIGO Stage II) with immunostaining of VEGF in the cytoplasm of tumor cells (400×; Evaluation: 4 points); (**I**) endometrioid ovarian adenocarcinoma (G3, FIGO Stage IV) with immunostaining of VEGF (400×; Evaluation: 7 points); (**J**) serous ovarian adenocarcinoma (G2, FIGO Stage II) with immunostaining of HIF-1α in the nuclei of tumor cells (400×; Evaluation: 1 point); (**K**) serous ovarian adenocarcinoma (G2, FIGO Stage III) with immunostaining of HIF-1α (400×; Evaluation: 5 points); (**L**) ovarian adenocarcinoma (G3 to undifferentiated, FIGO Stage III) with immunostaining of HIF-1α (400×; Evaluation: 7 points).](ijms-13-13264f1){#f1-ijms-13-13264}

![Kaplan-Meier analysis for the disease-free survival and overall survival of epithelial ovarian cancer patients according to SEMA4D expression in cancer cells. The survival curves were analyzed by the log rank test. (**A**) Epithelial ovarian cancer patients with positive SEMA4D expression showed shorter progress-free survival than those with negative expression; (**B**) Epithelial ovarian cancer patients with positive SEMA4D expression showed shorter overall survival than those with negative expression.](ijms-13-13264f2){#f2-ijms-13-13264}

###### 

SEMA4D, VEGF and HIF-1α expressions in ovarian cancers and normal tissues.

  Group          Cases (*N*)   SEMA4D positive expression *n* (%)   *p*       VEGF positive expression *n* (%)   *p*       HIF-1α positive expression *n* (%)   *p*
  -------------- ------------- ------------------------------------ --------- ---------------------------------- --------- ------------------------------------ ---------
  EOC tissues    124           76 (61.3)                            \<0.001   52 (41.9)                          \<0.001   60 (48.4)                            \<0.001
  normal ovary   40            4 (10)                                         4 (10)                                       2 (5)                                

###### 

Relationship of HIF-1α, VEGF and SEMA4D expression in EOC.

                                  Cases (*N*)   VEGF expression *n* (%)   *ρ*         *p*     HIF-1α expression *n* (%)   *ρ*         *p*            
  -------------------- ---------- ------------- ------------------------- ----------- ------- --------------------------- ----------- ----------- -- --
  SEMA4D               Negative   48            36 (75.0)                 12 (25.0)                                       36 (75.0)   12 (25.0)      
  expression *n* (%)   Positive   76            36 (47.4)                 40 (52.6)                                       28 (36.8)   48 (63.2)      
                                                                                      0.412   0.000                                                  
  HIF-1α               Negative   64            51 (79.7)                 13(20.3)                                                                   
  expression *n* (%)   Positive   60            21 (35.0)                 39 (65.0)                                                                  

###### 

Correlation between HIF-1α, VEGF and SEMA4D expressions with clinicopathologic characteristics of EOC patients.

  Variable                              Cases (*N*)   SEMA4D positive expression   VEGF positive expression   HIF-1α positive expression                       
  ------------------------------------- ------------- ---------------------------- -------------------------- ---------------------------- ------- ----------- -------
  Age                                                                              0.078                                                   0.431               0.276
  ≤50 years                             60            32 (53.3)                                               23 (38.3)                            26 (43.3)   
  \>50 years                            64            44 (68.8)                                               29 (45.3)                            34 (53.1)   
                                                                                                                                                               
  Menopausal status                                                                0.223                                                   0.913               0.401
  Yes                                   78            51 (65.4)                                               33 (42.3)                            40 (51.3)   
  No                                    46            25 (54.3)                                               19 (41.3)                            20 (43.5)   
                                                                                                                                                               
  Pathologic type                                                                  0.709                                                   0.581               0.390
  serous carcinoma                      80            50 (62.5)                                               35 (43.8)                            41 (51.3)   
  mucous and others                     44            26 (59.1)                                               17 (38.6)                            19 (43.2)   
  Histologic grade                                                                 0.000                                                   0.039               0.036
  G~1--2~                               49            20 (40.8)                                               15 (30.6)                            18 (36.7)   
  G~3~ or undifferentiated              75            56 (74.7)                                               37 (49.3)                            42 (56.0)   
                                                                                                                                                               
  FIGO Stage                                                                       0.016                                                   0.000               0.000
  I--II                                 53            26 (49.1)                                               8 (15.1)                             16 (30.2)   
  III--IV                               71            50 (70.4)                                               44 (62.0)                            44 (62.0)   
                                                                                                                                                               
  LN metastasis                                                                    0.017                                                   0.062               0.000
  No                                    74            39 (52.7)                                               26 (35.1)                            26 (35.1)   
  Yes                                   50            37 (74.0)                                               26 (52.0)                            34 (68.0)   
                                                                                                                                                               
  Residual disease                                                                 0.004                                                   0.304               0.060
  \<1 cm                                94            51 (54.3)                                               37 (39.4)                            41 (43.6)   
  ≥1 cm                                 30            25 (83.3)                                               15 (50.0)                            19 (63.3)   
                                                                                                                                                               
  Patients' response to chemotherapy                                               0.349                                                   0.010               0.108
  CR                                    87            51 (58.6)                                               30 (34.5)                            38 (43.7)   
  PR, SD and PD                         37            25 (67.6)                                               22 (59.5)                            22 (59.5)   
                                                                                                                                                               
  Tumors' sensitivity to chemotherapy                                              0.315                                                   0.006               0.149
  Platinum sensitive                    92            54 (58.7)                                               32 (34.8)                            41 (44.6)   
  platinum resistant and refractory     32            22 (68.8)                                               20 (62.5)                            19 (59.4)   

###### 

Univariate analysis of OS and PFS in EOC patients.

  Variable                              Cases (*N*)   Media of OS   χ*^2^*   *p*     Media of PFS   χ*^2^*   *p*
  ------------------------------------- ------------- ------------- -------- ------- -------------- -------- -------
  Age                                                               3.212    0.073                  1.830    0.176
  ≤50 years                             60            54                             41                      
  \>50 years                            64            43                             34                      
                                                                                                             
  Menopausal status                                                 0.076    0.782                  0.069    0.793
  Yes                                   78            48                                                     
  No                                    46            51                                                     
                                                                                                             
  Pathologic type                                                   0.354    0.552                  0.002    0.967
  serous carcinoma                      80            43                             41                      
  mucous and others                     44            53                             36                      
                                                                                                             
  Histologic grade                                                  26.047   0.000                  5.636    0.018
  G~1--2~                               49            85                             48                      
  G~3~ or undifferentiated              75            43                             33                      
                                                                                                             
  FIGO Stage                                                        32.221   0.000                  11.370   0.001
  I--II                                 53            68                             49                      
  III--IV                               71            39                             33                      
                                                                                                             
  LN metastasis                                                     17.484   0.000                  12.361   0.000
  No                                    74            56                             48                      
  Yes                                   50            35                             33                      
                                                                                                             
  Residual disease                                                  24.872   0.000                  5.824    0.016
  \<1cm                                 94            54                             41                      
  ≥1cm                                  30            35                             33                      
                                                                                                             
  Patients' response to chemotherapy                                16.060   0.000                  5.393    0.020
  CR                                    87            53                             40                      
  PR, SD and PD                         37            32                             34                      
                                                                                                             
  Tumors' sensitivity to chemotherapy                               10.502   0.001                  13.085   0.000
  Platinum sensitive                    92            53                             45                      
  platinum resistant and refractory     32            22                             10                      
                                                                                                             
  HIF-1α                                                            25.811   0.000                  4.639    0.031
  Negative                              64            59                             41                      
  Positive                              60            35                             36                      
                                                                                                             
  VEGF                                                              29.685   0.000                  1.945    0.163
  Negative                              72            58                             41                      
  Positive                              52            32                             34                      
                                                                                                             
  SEMA4D                                                            34.933   0.000                  16.541   0.000
  Negative                              48            NR                             49                      
  Positive                              76            41                             31                      

FIGO = International Federation of Gynecology and Obstetrics; NR = not reached; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.

###### 

Multivariate analysis with regard to OS and PFS.

                                        Overall survival   Disease-free survival                                           
  ------------------------------------- ------------------ ----------------------- ------- ------- ------- ------- ------- -------
  VEGF                                  0.185              0.709                   0.426   1.179                           
  Tumors' sensitivity to chemotherapy   0.053              0.493                   0.241   1.009   0.104   0.566   0.286   1.123
  Patients' response to chemotherapy    0.392              0.735                   0.363   1.488   0.392   0.735   0.363   1.488
  FIGO Stage                            0.033              0.540                   0.307   0.951   0.157   0.689   0.411   1.154
  LN metastasis                         0.793              1.068                   0.654   1.742   0.793   1.068   0.654   1.742
  Histologic grade                      0.019              0.509                   0.289   0.894   0.019   0.509   0.289   0.894
  HIF-1α                                0.113              0.671                   0.409   1.099   0.113   0.671   0.409   1.099
  SEMA4D                                0.001              0.395                   0.225   0.691   0.012   0.507   0.299   0.859
  Residual disease                      0.441              0.809                   0.471   1.389   0.403   0.813   0.500   1.321
